Mahmood Ahmad
Tahir Heart Institute
author@example.com

CT.gov Sponsor Ancient Backlog

Which named CT.gov sponsors still hold the largest stock of studies unresolved at least ten overdue years beyond the two-year reporting mark? We analysed 249,507 eligible older closed interventional studies from the March 29, 2026 full-registry snapshot. We defined ancient backlog as older studies with no posted results and at least ten overdue years beyond the two-year mark, then ranked sponsors with at least 100 studies. GlaxoSmithKline led the named-sponsor table at 1,045 studies, followed by National Cancer Institute at 787 and Boehringer Ingelheim at 748. Sanofi remained high on stock at 650, while Ranbaxy Laboratories Limited reached 100.0 percent and Mylan Pharmaceuticals Inc reached 96.8 percent among large sponsors. Ancient backlog isolates a harder core of silence than ordinary missing-results counts because these records remained unresolved for more than a decade after deadline. This registry-timing definition does not assign legal responsibility, explain delay, or prove total absence of dissemination outside linked CT.gov fields for readers.

Outside Notes

Type: methods
Primary estimand: Ancient-backlog stock among older closed interventional studies unresolved at least ten overdue years beyond the two-year mark
App: CT.gov Sponsor Ancient Backlog dashboard
Data: 249,507 eligible older closed interventional studies with ancient-backlog stock, rate, and overdue-years summaries
Code: https://github.com/mahmood726-cyber/ctgov-sponsor-ancient-backlog
Version: 1.0.0
Validation: FULL REGISTRY RUN

References

1. ClinicalTrials.gov API v2. National Library of Medicine. Accessed March 29, 2026.
2. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020;395(10221):361-369.
3. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov. N Engl J Med. 2016;375(20):1998-2004.

AI Disclosure

This work represents a compiler-generated evidence micro-publication built from structured registry data and deterministic summary code. AI was used as a constrained coding and drafting assistant for interface generation, packaging, and prose refinement, not as an autonomous author. The analytical choices, interpretation, and final outputs were reviewed by the author, who takes responsibility for the content.